Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats

Brazilian Journal of Otorhinolaryngology

Volumn 75, Issue 4, 2009, Pages 476-484

  De Freitas, Marcos Rabelo ^a   Da Silva, Viviane Carvalho ^a   Brito, Gerly Anne De Castro ^a   De Carvalho Jr , José Valdir ^a   Gomes Jr , Raimundo Martins ^a   Ribeiro, Ronaldo De Albuquerque ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Cisplatin; Hearing; Hearing loss

Indexed keywords

CISPLATEX; CISPLATIN; KETAMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; XYLAZINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY THRESHOLD; CLINICAL ASSESSMENT; CONTROL GROUP; CONTROLLED STUDY; DILUTION; DISTORTION PRODUCT OTOACOUSTIC EMISSION; ELECTROPHYSIOLOGY; EVOKED BRAIN STEM AUDITORY RESPONSE; FREEZE DRYING; HEARING; MALE; MICROSCOPY; NONHUMAN; OTOSCOPY; OTOTOXICITY; RAT; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; WISTAR RAT;

EID: 70349255643     PISSN: 18088694     EISSN: 18088686     Source Type: Journal    
DOI: 10.1016/S1808-8694(15)30483-3     Document Type: Article

References (59)

1. Jordan J, Schwade ND, Truelson JM. Fosfomycin does not inhibit the tumoricial efficacy of cisplatinum. Laryngoscope. 1999;109(8):1259-1262 (Pubitemid 29379436)
2. Guneri EA, Serbetçiogllu B, Ikiz AO, Guneri A, Ceryan K. TEOAE monitoring of cisplatin induced ototoxicity in guinea pigs: the protective effect of vitamin B treatment. Auris Nasus Larynx. 2001;28:9-14. (Pubitemid 32008620)
3. Feghali JG, Liu W, Water TRVD. L-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope. 2001;111:1147-1155 (Pubitemid 32625400)
4. Strauss M, Towfighi J, Lipton A, Brown B, Lord S, Harvey H. Cisplatinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope. 1983; 93:1554-1559 (Pubitemid 14204680)
5. Schaefer SD, Post JD, Close LG, Wright CG. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985;56:1934-1939
6. Laurell G, Jungelius U. High dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope. 1990;100:724-734 (Pubitemid 20222873)
7. Reddel RR, Kefford RF, Grant JM, Coats AS, Fox RM, Tarttersall MHN. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19-23.
8. Allen GC, Tiu C, Koike K, Ritchey AK, Kurs-Lasky M, Wax MK. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg. 1998;118(5):584-588 (Pubitemid 28222198)
9. Wright CG, Schaefer SD. Inner ear histopathology in patients treated with cisplatinum. Laryngoscope. 1982;92(12):1408-1413 (Pubitemid 13203794)
10. Laurell G, Frankendal B, Borg E. Cisplatin administration to gynecologic cancer patients: long term effects on hearing. Cancer. 1996;78(8):1798-1884 (Pubitemid 26330910)
11. Kopke RD, Liu W, Gabizadeh R., Jacono A, Feghali J, Spray D, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otolaryngol. 1997;18:559-571 (Pubitemid 27428342)
12. Cardinaal RM, De Groot JCMJ, Huizing EH, Veldman JE, Smoorenburg GF. Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res. 2000;144:135-146
13. Bagger-Sjöbäck D, Filipek CS, Schacht J. Characteristics and drug responses of cochlear and vestibular adenylate cyclase. Arch Otorhinolaryngol. 1980;228:217-222 (Pubitemid 10046713)
14. Komune S, Asakuma S, Snow JB. Pathophysiology of the ototoxicity effect of cisdiamminedichloroplatinum. Otolaryngol Head Neck Surg. 1981;89:275-282
15. Saito T, Aran JM. Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL J Otorhinolaryngol Relat Spec. 1994;56(6):315-320
16. Campbell KCM, Meech RP, Rybak LP, Hughes LFD-Methionine protects against cisplatin damage to the stria vascularis. Hear Res. 1999;138:13-28.
17. Smoorenburg GF, De Groot JCMJ, Hamers FPT, Klis SFL. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann. N Y Acad Sci. 1999;28:192-210.
18. Smoorenburg GF, De Groot JCMJ, Hamers FPT, Klis SFL. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pig? Hear Res. 2000;144:147-156
19. Smoorenburg GF, De Groot JCMJ, Hamers FPT, Klis SFL. Histological Effects of co-administration of an ACTH4-9 analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig. Hear Res. 2000;144:157-167
20. O'Leary SJ, Klis SFL, De Groot JCMJ, Hamers FPT, Smoorenburg GF. Perilymphatic application of cisplatin over several days in albino guinea pigs: dose dependency of electrophysiological and morphological effects. Hear Res. 2001;154:135-145
21. Sluyter S, Klis SFL, De Groot JCMJ, Smoorenburg GF. Alterations in the stria vascularis in relation to cisplatin ototoxicity and recovery. Hear Res. 2003;185:49-56. (Pubitemid 37346392)
22. Lynch ED, Gu R, Pierce C, Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res. 2005;201:81-89 (Pubitemid 40255547)
23. Van Ruijven MWM, De Groot JCMJ, Smoorenburg GF. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res. 2004;197:44-54.
24. Van Ruijven MWM, De Groot JCMJ, Klis SFL, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005;205:241-248
25. Laurell G, Bagger-Sjöbäck D. Dose-dependent inner ear changes after I.V. administration of cisplatin. J Otolaryngol. 1991;20:158-167
26. De Groot JCMJ, Hamers FPT, Gispen WH, Smoorenburg GF. Co-administration of the neurotrophic ACTH(4-9) analogue, ORG 2766, may reduce the cochleotoxic effects of cisplatin. Hear Res. 1997;106 (1-2): 9-19.
27. Oliveira JAA, Canedo DM, Rossato M. Otoproteção das células ciliadas auditivas contra a ototoxicidade da amicacina. Rev Bras Otorrinolaringol. 2002;68 (1):7-13.
28. Kamimura T, Whitworth CA, Rybak LP. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear Res. 1999;131:117-127 (Pubitemid 29210401)
29. Rybak LP, Husain K, Morris C, Whitworth C, Somani. S. Effect of protective agents against cisplatin ototoxicity. Am J Otolaryngol. 2000;21:513-520 (Pubitemid 30432460)
30. Sockalingam R, Freeman S, Cherny L, Sohmer H. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals. Am J Otol. 2000;21:521-527 (Pubitemid 30432461)
31. Hyppolito MA, Oliveira JAA, Lessa RM, Rossato M. Otoproteção da amifostina aos efeitos ototóxicos da cisplatina em cobaias albinas por emissões otoacústicas produtos de distorção e microscopia eletrônica de varredura. Rev Bras Otorrinolaringol. 2005;71 (3): 268-273 (Pubitemid 41152569)
32. Hyppolito MA, Oliveira JAA, Rossato M, Holanda F. Ototoxicidade da cisplatina e otoproteção pelo extrato de ginkgo biloba às células ciliadas externas: estudo anatômico e eletrofisioló gico. Rev Bras Otorrinolaringol. 2003;69 (4): 504-511
33. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA. Protection against cisplatin-induced ototoxicity by Nacetylcysteine in a rat model. Hear Res. 2004;193:25-30. (Pubitemid 38813422)
34. Amsallem P, Andrieu-Guitrancourt J. Étude exppérimentale de l'ototoxicité du cisplatinum. Ann Otolaryngol Chir Cervicofac. 1985;102 (5):365-372
35. Schweitzer VG, Hawkings JE, Lilly DJ, Litterst CJ, Abrams G, Davis JA. Ototoxic and nephrotoxic effects of combined treatment with cis- diamminedichloroplatinum and kanamycin in the guinea pig. Otolaryngol Head Neck Surg. 1984;92 (1): 38-49.
36. Lopez-Gonzalez MA, Guerrero JM, Rojas F, Delgado F. Ototoxicity caused by cisplatin ameliorated by melatonin and other antioxidants. J Pineal Res. 2000;28:73-80. (Pubitemid 30125171)
37. Hatzopoulos S, Di Stefano M, Albertin A, Martini A. Evaluation of cisplatin ototoxicity in a rat animal model. Ann N Y Acad Sci. 1999;28:211-225
38. Mcalpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res. 1990;47:191-204.
39. Azevedo MF. Emissões otoacústicas. In: Figueredo MS. Emissões otoacústicas e BERA. São José dos Campos: Editora Pulso; 2003. 35-83.
40. Tange RA, Vuzevski VD. Change in the stria vascular of the guinea pig due to cis-platinum. Arch Otorhinolaryngol. 1984;239:41-47
41. Rebert CS, Pryor GT, Frick MS. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiological indices of neurotoxicity in the rat. J Appl Toxicol. 1984;4 (6): 330-338
42. Hatzopoulos S, Petriccelli J, Laurell G, Avan P, Finesso M, Martini A. Ototoxic effects of cisplatin in a Sprague-Dawley rat animal model as reveled by ABR and transiently evoked otoacoustic emission measurements. Hear Res. 2002;170:70-82.
43. Rybak LP, Somani S. Ototoxicity. Amelioration by protective agents. Ann N Y Acad Sci. 1999;28:143-151
44. Rybak LP, Husain K, Whitworth C, Somani SM. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system. Toxicol Sci. 1999;47:195-202. (Pubitemid 29214827)
45. Rybak LP, Whitworth CMA, Somani S. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope .1999;109 (11):1740-1744 (Pubitemid 29533912)
46. Laurell G, Viberg A, Teixeira M, Sterkers O, Ferrary E. Blood-perilymph barrier and ototoxicity: an in vivo study in rat. Acta Otolaryngol. 2000;120:796-803. (Pubitemid 32511248)
47. Oh SH, Yu WS, Song B-H, Lim D, Koo J-W, Chang SO, et al. Expression of heat shock protein 72 in rat cochlea with cisplatin-induced acute ototoxicity. Acta Otolaryngol. 2000;120:146-150
48. Tanaka F, Whitworth CA, Rybak LP. Round window pH manipulation alters the ototoxicity of systemic cisplatin. Hear Res. 2004;187:44-50. (Pubitemid 38091561)
49. Kalkanis JK, Whitworth MA, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope. 2004;114 (3): 538-542
50. Minami SB, Sha S-H, Schacht J. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res. 2004;198 (1-2): 137-143 (Pubitemid 39536163)
51. Hood LJ. Stimulus, recording, and patient factors influencing the ABR. In: Hood LJ. Clinical applications of the auditory brainstem responses. San Diego: Singular Publishing Group;1998.
52. Li G, Frenz DA, Brahmblatt S, Feghali JG, Ruben RJ, Berggren D, et al. Round window membrane delivery of l-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology. 2001;22:163-176 (Pubitemid 32499698)
53. Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol. 1995;26 (2): 293-300.
54. Martin M, Moore E. Scalp distribution of early (0 to 10 msec) auditory evoked responses. Arch Otolaryngol. 1977;103: 326-328 (Pubitemid 8123794)
55. Campbell KCM, Rybak LP, Meech RP. D-Methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res. 1996;102:90-98
56. Cheng AG, Cunningham LL, Rubell EW. Mechanisms of hair cell death and protection. Curr Opin Otolaryngol Head Neck Surg. 2005;13: 343-348 (Pubitemid 41682251)
57. Möller M. Frequency representation in the rat cochlea. Hear Res. 1991;51: 247-254
58. Estrem SA, Babin RW, Ryu JH, Moore KC. Cisdiamminedichloroplatinum (II) ototoxicity in guinea pig. Otolaryngol Head Neck Surg. 1981;89: 638-645
59. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of thiossulfate of sodium, diethylditiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res. 1995;86 (1-2):195-203.